$2.72
-0.07-2.51%
At Close: -
$2.70
-0.02-0.74%
After Hours: 1:18 PM EDT
15 minutes delayed
RAPT Therapeutics
RAPTNASDAQ
RAPT Therapeutics (NASDAQ:RAPT) Stock, Analyst Ratings, Price Targets, Predictions
RAPT Therapeutics Inc has a consensus price target of $21.06, established from looking at the 44 latest analyst ratings. The last 3 analyst ratings were released from Barclays, JP Morgan, and UBS on May 10, 2024, March 27, 2024, and February 22, 2024. With an average price target of $9 between Barclays, JP Morgan, and UBS, there's an implied 233.33% upside for RAPT Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wolfe Research
Barclays
Guggenheim
HC Wainwright & Co.
JP Morgan
1calculated from analyst ratings
Analyst Ratings for RAPT Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 05/10/2024 | Buy Now | 48.15% | Barclays | Leon Wang | $13 → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 04/10/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 03/27/2024 | Buy Now | 381.48% | JP Morgan | Anupam Rama | $15 → $13 | Maintains | Neutral | Get Alert |
| 02/22/2024 | Buy Now | 270.37% | UBS | Eliana Merle | $61 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 381.48% | Barclays | Leon Wang | $35 → $13 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 270.37% | Leerink Partners | Thomas Smith | → $10 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/21/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 455.56% | JP Morgan | Anupam Rama | $35 → $15 | Downgrade | Overweight → Neutral | Get Alert |
| 02/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal | — | Downgrade | Overweight → Neutral | Get Alert |
| 02/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 02/15/2024 | Buy Now | 1344.44% | Wolfe Research | Andy Chen | → $39 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 1196.3% | JP Morgan | Anupam Rama | $32 → $35 | Maintains | Overweight | Get Alert |
| 11/15/2023 | Buy Now | 1418.52% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 1159.26% | Berenberg | Andy Chen | → $34 | Initiates | → Buy | Get Alert |
| 08/16/2023 | Buy Now | 1085.19% | JP Morgan | Anupam Rama | $39 → $32 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 1048.15% | Piper Sandler | Edward Tenthoff | $28 → $31 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 1418.52% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 1381.48% | Stifel | Alex Thompson | → $40 | Initiates | → Buy | Get Alert |
| 06/15/2023 | Buy Now | 1196.3% | Barclays | Leon Wang | → $35 | Initiates | → Overweight | Get Alert |
| 06/05/2023 | Buy Now | 1418.52% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 1418.52% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $41 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | 1492.59% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | 1455.56% | JP Morgan | Anupam Rama | $48 → $42 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 1492.59% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 1677.78% | Guggenheim | Yatin Suneja | $55 → $48 | Maintains | Buy | Get Alert |
| 03/15/2023 | Buy Now | 751.85% | Goldman Sachs | Corinne Jenkins | $27 → $23 | Maintains | Buy | Get Alert |
| 03/15/2023 | Buy Now | 1492.59% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $43 | Maintains | Buy | Get Alert |
| 01/04/2023 | Buy Now | 1937.04% | Guggenheim | Yatin Suneja | → $55 | Initiates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 1677.78% | Wells Fargo | Yanan Zhu | $55 → $48 | Maintains | Overweight | Get Alert |
| 12/01/2022 | Buy Now | 900% | Goldman Sachs | Corinne Jenkins | → $27 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 1751.85% | HC Wainwright & Co. | Raghuram Selvaraju | $53 → $50 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 1159.26% | Piper Sandler | Edward Tenthoff | $30 → $34 | Maintains | Overweight | Get Alert |
| 09/21/2022 | Buy Now | 1677.78% | Capital One | Zegbeh Jallah | → $48 | Initiates | → Overweight | Get Alert |
| 08/12/2022 | Buy Now | 1862.96% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $53 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | 1677.78% | SVB Leerink | Mike Kratky | $49 → $48 | Maintains | Outperform | Get Alert |
| 06/23/2022 | Buy Now | 1751.85% | HC Wainwright & Co. | Raghuram Selvaraju | $56 → $50 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 1529.63% | Cantor Fitzgerald | Prakhar Agrawal | → $44 | Assumes | → Overweight | Get Alert |
| 05/12/2022 | Buy Now | 1011.11% | Piper Sandler | Edward Tenthoff | $52 → $30 | Maintains | Overweight | Get Alert |
| 03/11/2022 | Buy Now | 1825.93% | Piper Sandler | Edward Tenthoff | $61 → $52 | Maintains | Overweight | Get Alert |
| 03/11/2022 | Buy Now | 1937.04% | Wells Fargo | Yanan Zhu | $65 → $55 | Maintains | Overweight | Get Alert |
| 12/09/2021 | Buy Now | 2159.26% | JP Morgan | Anupam Rama | — | Initiates | → Overweight | Get Alert |
| 08/12/2021 | Buy Now | 1714.81% | SVB Leerink | Thomas Smith | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for RAPT Therapeutics (RAPT) stock?
The latest price target for RAPT Therapeutics (NASDAQ:RAPT) was reported by Wolfe Research on May 14, 2024. The analyst firm set a price target for $0.00 expecting RAPT to fall to within 12 months (a possible -100.00% downside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RAPT Therapeutics (RAPT)?
The latest analyst rating for RAPT Therapeutics (NASDAQ:RAPT) was provided by Wolfe Research, and RAPT Therapeutics downgraded their peer perform rating.
When was the last upgrade for RAPT Therapeutics (RAPT)?
There is no last upgrade for RAPT Therapeutics
When was the last downgrade for RAPT Therapeutics (RAPT)?
The last downgrade for RAPT Therapeutics Inc happened on May 14, 2024 when Wolfe Research changed their price target from N/A to N/A for RAPT Therapeutics Inc.
When is the next analyst rating going to be posted or updated for RAPT Therapeutics (RAPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating RAPT Therapeutics (RAPT) correct?
While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a downgraded with a price target of $0.00 to $0.00. The current price RAPT Therapeutics (RAPT) is trading at is $2.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.